AstraZeneca and the Department of Health and Human Services have signed a potential $1.2B public-private partnership agreement to further develop a recombinant adenovirus vaccine as potential treatment for the novel coronavirus.
The company paid cash for Praha Vaccines a.s., part of the Cyrus Poonawalla Group.
Novavax has begun enrolling particpants in a Phase I/II trial assessing its coronavirus vaccine candidate NVX-CoV2373.
"Manufacturing capacity is a critical component of our strategy to deliver a vaccine for the COVID-19 pandemic", said Stanley C. Erck, President and Chief Executive Officer of Novavax.
KAZINFORM Thai COVID-19 vaccine research team on Monday said it will be recruiting human beings for vaccine trials later this year following an ongoing three months test on monkeys. "In parallel with ramping up production at Bohumil, we will continue efforts to expand antigen capacity in the USA and Asia, and increase production of Matrix-M to match antigen capacity at multiple sites globally".
Novavax was reported trading up in premarket trading on Tuesday. The partners in March agreed to use Novavax's proprietary Matrix-M™ vaccine adjuvant with SII's malaria vaccine candidate, now in a Phase IIb clinical trial. It's not clear that any will prove safe and effective. Volunteers were enrolled from one site in Wuhan, China, and assigned to receive either a single intramuscular injection of the new Ad5 vaccine at a low dose (5 × 1010 viral particles/0·5ml, 36 adults), middle dose (1×1011 viral particles/1.0ml, 36 adults), or high dose (1.5 x 1011 viral particles/1.5ml, 36 adults).
India sees biggest spike in COVID-19 with 6,767 cases
As per the John Hopkins University, the United States has the highest number of coronavirus cases around the world at 16,43,246. With 160 deaths in 24 hours, the number of deaths due to COVID-19 stands at 4,021, as per government data.
The company has plans to produce up to 100 million vaccine doses by the end of this year, scaled up to more than a billion doses during 2021.
The Coalition for Epidemic Preparedness Innovations had earlier invested as much as $4 million in the company's coronavirus vaccine program.
Novavax said it expects preliminary immunogenicity and safety results from the trial in July.
Most of the vaccines in the pipeline aim to train the immune system to recognise the "spike" protein that studs the coronavirus' outer surface, priming the body to react if it ever encountered the real infection. Still other candidate vaccines are more outdated, made from complete dead viruses. Novavax developed copies of the protein in giant laboratory vats of insect cells, which were extracted and purified by researchers who packaged the spike protein into virus-sized nanoparticles. These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, potentially leading to protection from COVID-19 and thus helping to control the spread of this disease.
July is reportedly when the first results of the trial will be ready after time has been given to make sure those that tested have developed the required amount of antibodies to be considered immune to the virus.
It's the identical course of that Novavax used to create a nanoparticle flu vaccine that lately handed late-stage testing.